ALN-CC5 Historical Press Releases
Below is a list of historical press releases related to our ALN-CC5 program for the treatment of Complement-Mediated Disease: 2014 January 10: Alnylam Provides Key 2014 Goals for RNAi Therapeutics...
View ArticleImage-based Analysis of Lipid Nanoparticle–mediated siRNA Delivery,...
Gilleron et al., Nat Biotechnol. 2013 Jun23 (Epub doi:10.1038/nbt.2612) Abstract: Delivery of short interfering RNAs (siRNAs) remains a key challenge in the development of RNA interference (RNAi)...
View ArticleClik here to view.
Efficiency of siRNA Delivery by Lipid Nanoparticles is Limited by Endocytic...
Sahay et al., Nat Biotechnol. 2013 Jun23 (Epub doi:10.1038/nbt.2614) Abstract: Despite efforts to understand the interactions between nanoparticles and cells, the cellular processes that determine the...
View ArticleBiodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for...
Maier et al., Mol Ther. 2013 Jun25 (Epub doi: 10.1038/mt.2013.124) Abstract In recent years, RNA interference (RNAi) therapeutics, most notably with lipid nanoparticle-based delivery systems, have...
View ArticlePositive Clinical Trial Results with ALN-TTR01 and ALN-TTR02 Published in the...
We have published complete study results from Phase I trials with ALN-TTR01 and ALN-TTR02 in the New England Journal of Medicine. RNAi therapeutics targeting transthyretin (TTR) achieved rapid,...
View ArticleSafety and Efficacy of RNAi Therapy of RNAi Therapy for Transthyretin...
Coelho et al., NEJM. 2013 Sept13 (Epub doi: 10.1056/NEJMoa1208760 ) Abstract Transthyretin amyloidosis is caused by the deposition of hepatocyte-derived transthyretin amyloid in peripheral nerves and...
View ArticlePositive Phase I Clinical Trial Results with ALN-PCS Published in “The Lancet”
We have published complete study results from our Phase I trial with ALN-PCS in The Lancet. As reported in the paper, ALN-PCS administration resulted in a rapid, dose-dependent reduction in plasma...
View ArticleALN-ANG Historical Press Releases
For your convenienence we have collected a list of historical press releases that cover the historical progess of our clinical program for mixed hyperlipidema and severe hypertriglyceridemia 2013...
View ArticleClik here to view.
Novel Method for Detection of Tissue-Specific, RNAi-Mediated Gene Silencing...
We have published a paper in the journal RNA describing a novel method that enables the quantification of circulating messenger RNA (mRNA) and micro-RNA (miRNA) as a way of monitoring tissue-specific...
View ArticlePre-Clinical Results with RNAi Therapeutics Targeting Aminolevulinic Acid...
We have published pre-clinical results with RNAi therapeutics targeting aminolevulinic acid synthase-1 (ALAS-1) for the treatment of hepatic porphyrias in the Proceedings of the National Academy of...
View ArticleNew Paper Documenting Alnylam’s Pioneering Discovery of GalNAc-Conjugated siRNA
We have published an article in the Journal of the American Chemical Society describing the discovery of GalNAc-conjugated siRNA as a novel strategy for delivery of RNAi therapeutics. This publication...
View ArticlePre-Clinical Results with ALN-AT3 Published in “Nature Medicine”
We have published pre-clinical results with ALN-AT3, an investigational RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia, in Nature Medicine. The paper documents a broad set...
View ArticleWelcome to Alnylam
Alnylam is developing an entirely new class of medicines based on the breakthrough discovery in biology known as RNA interference, or RNAi. Alnylam believes that RNAi therapeutics are a promising...
View ArticleAlnylam Announces Key Pipeline Goals for 2014
In January 2014, we shared our key pipeline goal for the year. Indeed, as a result of the achievements of the past period, we now believe that we will exceed our original ‘Alnylam 5×15’ guidance as...
View ArticleAlnylam Acquires Merck’s wholly owned subsidiary, Sirna Therapeutics
In January 2014, we entered an agreement with Merck, whereby we are acquiring Merck’s wholly owned subsidiary Sirna Therapeutics, Inc. This acquisition provides us with intellectual property and RNAi...
View ArticleAlnylam and Genzyme Form Transformational Alliance for RNAi Therapeutics as...
In January 2014, Alnylam and Genzyme formed a transformational alliance with Genzyme for the development and commercialization of RNAi therapeutics as genetic medicines. This new alliance will allow...
View ArticleComplete Study Results from our ALN-VSP Phase I Trial and Extension Study...
We have published complete study results from our Phase I clinical trial with ALN-VSP, an RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. Results from the study –...
View ArticleAPOLLO Phase 3 Trial Methodology Published in BMC Neurology
A paper describing the rationale and design of the APOLLO Phase 3 study was published in BMC Neurology. APOLLO was a randomized, double-blind, placebo-controlled, global study evaluating the efficacy...
View ArticleComplete Study Results from our ALN-VSP Phase I Trial and Extension Study...
We have published complete study results from our Phase I clinical trial with ALN-VSP, an RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. Results from the study –...
View ArticleAPOLLO Phase 3 Trial Methodology Published in BMC Neurology
A paper describing the rationale and design of the APOLLO Phase 3 study was published in BMC Neurology. APOLLO was a randomized, double-blind, placebo-controlled, global study evaluating the efficacy...
View Article
